AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2021
Feb 26, 2021
29864_dirs_2021-02-26_e66e0f39-1ca8-4b0a-a6bd-f5dc8c3c193b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-02-24
Reporting Person: ALTSHULER DAVID (EVP, Global Research and CSO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-24 | Common Stock | F | 2416 | $217.57 | Disposed | 36617 | Direct |
| 2021-02-25 | Common Stock | S | 646 | $211.58 | Disposed | 35971 | Direct |
| 2021-02-25 | Common Stock | S | 1348 | $213.05 | Disposed | 34623 | Direct |
| 2021-02-25 | Common Stock | S | 680 | $214.28 | Disposed | 33943 | Direct |
| 2021-02-25 | Common Stock | S | 354 | $216.26 | Disposed | 33589 | Direct |
Footnotes
F1: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $211.58 (range $211.34 to $211.91).
F3: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $213.05 (range $212.76 to $213.68).
F5: Open market sales reported on this line occurred at a weighted average price of $214.28 (range $213.90 to $214.69).
F6: Open market sales reported on this line occurred at a weighted average price of $216.26 (range $215.79 to $216.76).